Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

Ann Oncol. 2019 Nov 1;30(11):1842. doi: 10.1093/annonc/mdz215.
No abstract available

Publication types

  • Published Erratum